Financing
Stock Issuance Proceeds
Year-over-year, this metric grew by 2.1%, from $29.70M to $30.31M. Over 4 years (FY 2021 to FY 2025), Stock Issuance Proceeds shows an upward trend with a 32.2% CAGR.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher proceeds often correlate with employee participation in stock-based compensation programs rather than external capital raising.
Detailed definition
Cash inflows resulting from the issuance of common stock, typically through employee stock option exercises or equity co...
Peer comparison
Standard for large-cap companies with significant equity-based compensation programs.
Metric ID:
proceeds_from_stock_issuanceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $262.93M | $0.00 | $0.00 | $6.82M | -$6.82M | $33.38M | $258.77M | $1.14M | $36.88M | $0.00 | $114.46M | $4.05M | $709.11M | $370.98M | $0.00 | $29.70M | $793.83M | -$256.00K | $0.00 | $30.31M |
| QoQ Change | — | -100.0% | — | — | -200.0% | +589.6% | +675.2% | -99.6% | >999% | -100.0% | — | -96.5% | >999% | -47.7% | -100.0% | — | >999% | -100.0% | +100.0% | — |
| YoY Change | — | — | — | — | -102.6% | — | — | -83.3% | +640.8% | -100.0% | -55.8% | +255.8% | >999% | — | -100.0% | +633.1% | +11.9% | -100.1% | — | +2.1% |
Range-$6.82M – $793.83M
CAGR-36.5%
Avg YoY Growth+235.4%
Median YoY Growth-26.9%
Current Streak2 quarters growth
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Insmed's stock issuance proceeds?
- Insmed (INSM) reported stock issuance proceeds of $30.31M in Q1 2026.
- How has Insmed's stock issuance proceeds changed year-over-year?
- Insmed's stock issuance proceeds increased by 2.1% year-over-year, from $29.70M to $30.31M.
- What is the long-term trend for Insmed's stock issuance proceeds?
- Over 4 years (2021 to 2025), Insmed's stock issuance proceeds has grown at a 32.2% compound annual growth rate (CAGR), from $269.89M to $823.28M.
- What does stock issuance proceeds mean?
- Cash received from the sale or issuance of company stock.